Novartis AG (ADR)  

(Public, NYSE:NVS)   Watch this stock  
Find more results for NVS
76.11
-0.73 (-0.95%)
May 3 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 75.93 - 76.56
52 week 69.89 - 106.84
Open 76.45
Vol / Avg. 2.13M/2.36M
Mkt cap 204.74B
P/E 27.45
Div/yield 2.72/3.57
EPS 2.77
Shares 2.38B
Beta 0.59
Inst. own 10%
Jul 19, 2016
Q2 2016 Novartis AG Earnings Release Add to calendar
Jun 23, 2016
Novartis AG at JPMorgan European Healthcare Conference Add to calendar
Jun 22, 2016
Novartis AG at Citi European Healthcare Conference Add to calendar
Jun 8, 2016
Novartis AG at Goldman Sachs European Financials Conference Add to calendar
May 25, 2016
Novartis AG Meet Novartis Management - 2:00AM EDT - Add to calendar
Apr 21, 2016
Q1 2016 Novartis AG Earnings Call
Apr 21, 2016
Q1 2016 Novartis AG Earnings Release
Mar 31, 2016
Novartis AG Updated 2015 Segment Financials Reflecting New Division Structure Corporate Call
Mar 15, 2016
Novartis AG at Exane Bnp Healthcare Conference
Mar 9, 2016
Novartis AG at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 17.03% 13.96%
Operating margin 20.33% 17.56%
EBITD margin - 31.53%
Return on average assets 6.11% 5.47%
Return on average equity 10.84% 9.49%
Employees 118,000 -
CDP Score - 98 B

Address

Lichtstrasse 35
BASEL, 4056
Switzerland
+41-61-3241111 (Phone)
+41-61-3247826 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Company's segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Officers and directors

Joerg Reinhardt Ph.D. Chairman of the Board of Directors
Age: 60
Bio & Compensation  - Reuters
Joseph Jimenez Chief Executive Officer, Member of the Executive Committee
Age: 56
Bio & Compensation  - Reuters
Harry Kirsch Chief Financial Officer, Member of the Executive Committee
Age: 50
Bio & Compensation  - Reuters
Felix R. Ehrat Ph.D. Group General Counsel, Member of the Executive Committee
Age: 59
Bio & Compensation  - Reuters
Steven Baert Head of Human Resources and Member of the Executive Committee
Age: 41
Bio & Compensation  - Reuters
David R. Epstein Member of the Executive Committee, Division Head, Pharmaceuticals
Age: 54
Bio & Compensation  - Reuters
Mark C. Fishman M.D. Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)
Age: 64
Bio & Compensation  - Reuters
Richard Francis Member of the Executive Committee and Division Head, Sandoz
Age: 47
Bio & Compensation  - Reuters
Jeffrey George Member of the Executive Committee and Division Head, Alcon.
Age: 42
Bio & Compensation  - Reuters
Andre Wyss Member of the Executive Committee, Global Head, Novartis Business Services and Country President for Switzerland
Age: 48
Bio & Compensation  - Reuters